NCT06040424Active, not recruitingPhase 3
Randomized, Parallel Group, Phase III, Non-inferiority Study Comparing Ipratropium / Levosalbutamol Fixed Dose Combination in pMDI Form and Ipratropium and Salbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD)
Neutec Ar-Ge San ve Tic A.Ş1 site in 1 country74 target enrollmentStarted: September 28, 2023Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 74
- Locations
- 1
- Primary Endpoint
- FEV1 area under the curve from 0-8 h (FEV1 AUC 0-8 h)
Study Overview
Brief Summary
The goal of this clinical trial is to compare the acute bronchodilator effect of pMDI formed Ipratropium / Levosalbutamol 20 mcg / 50 mcg fixed dose combination or pMDI formed Salbutamol 100 mcg Inhaler and Ipratropium 20 mcg Inhalation Aerosol in combination in stable moderate-severe-very severe COPD patients.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 40 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female patients aged 40 years and older who have been newly diagnosed or followed up with a diagnosis of COPD.
- •Stable moderate-severe-very severe COPD patients with a post-bronchodilator FEV1/FVC ratio <70% and a postbronchodilator FEV1 value <80% at the screening visit will be included in the study.
- •Symptom status such as chronic cough, sputum production, and progressive dyspnea with the BCSS (Breathlessness, Cough and Sputum Scale) Index will be evaluated, and the COPD staging of the patient with CAT (COPD Assessment Test) and the severity of dyspnea with mMRC (Modified Medical Research Council) will be determined.
- •Patients with at least 10 pack/year smoking status or smoking history (patients who have quit smoking for at least 6 months or more are defined as ex-smokers).
- •Patients who have not experienced an exacerbation in the previous 4 weeks.
- •If the study participant is female; women using appropriate contraception (pregnancy test will be performed at screening visit).
- •Patients with the ability to communicate with the investigator.
- •Patients who accept to comply with the protocol.
- •Patients who sign written informed consent form.
Exclusion Criteria
- •History of hypersensitivity to anticholinergics or SABAs (short acting beta agonist).
- •History of COPD exacerbation or lower respiratory track infection that required treatment with antibiotic, oral or parenteral corticosteroid within the last 3 days prior the screening visit or during the run-in/wash-out period or history of respiratory tract infection that required treatment with antibiotic within the last 14 days prior the screening visit.
- •Hospitalization due to COPD or pneumonia within the last 3 mounts prior the screening visit.
- •SGOT (serum glutamic-oxaloacetic transaminase) >80 IU/L, SGPT (serum glutamic-pyruvic transaminase) >80 IU/L, bilirubin >2.0 mg/dL or creatinine >2.0 mg/dL.
- •History of asthma, significant chronic respiratory diseases (i.e., significant bronchiectasis, interstitial lung diseases, etc.) other than COPD or presence of disease that may be serious and/or potentially affect results of the study.
- •Use of beta-blocker, monoamine oxidase (MAO) inhibitor or tricyclic antidepressant within the last 30 days prior the screening visit
- •Recent (within ≤3 months prior the screening visit) history of heart attack, heart failure, acute ischemic heart disease or presence of serious cardiac arrhythmia requiring drug treatment.
- •Regularly use of daytime CPAP (continuous positive airway pressure) oxygen therapy for longer than 1 hour per day.
- •Initiation of pulmonary rehabilitation within the 3 months prior the screening visit.
- •History of lung volume reduction surgery
- •Drug or alcohol abuse
- •Presence of active tuberculosis
- •History of atopy or allergic rhinitis
- •Presence of active cancer
- •Attenuated live virus vaccination within the last 2 weeks prior the screening visit or during the run-in/wash-out period
- •Pregnancy or lactation
- •Presence of known symptomatic prostatic hypertrophy requiring treatment
- •Presence of known narrow-angle glaucoma requiring treatment
- •Currently participating in another clinical trial or treatment with another investigational study drug within the last month or 6-half-lives, whichever is longer.
Arms & Interventions
Ipratropium / Levosalbutamol Fixed Dose Combination
Experimental
In this one-day study, patients will be administered 2 inhalation of "İPRALEV 20 mcg/50 mcg aerosol inhalasyonu, süspansiyon" at morning.
Intervention: Ipratropium / Levosalbutamol Fixed Dose Combination (Combination Product)
Ipratropium + Levosalbutamol Free Dose Combination
Active Comparator
In this one-day study, patients will be administered 2 inhalations of "VENTOLİN İnhaler 100 mcg" and then 2 inhalations of "ATROVENT MDI 0,02 mg/dose" at morning.
Intervention: Ipratropium + Levosalbutamol Free Dose Combination (Drug)
Outcomes
Primary Outcomes
FEV1 area under the curve from 0-8 h (FEV1 AUC 0-8 h)
Time Frame: 8 hours
Change From Baseline in Forced Expiratory Volume in one second (FEV1) Area Under the Curve (AUC) 0-8h.
Secondary Outcomes
- FVC AUC 0-3 h(3 hours)
- FEV1 AUC 3-6 h(3 to 6 hours)
- FEV1 AUC 6-8 h(6 to 8 hours)
- FVC AUC 6-8 h(6 to 8 hours)
- FVC AUC 0-8 h(0 to 8 hours)
- Mean Maximum Change From Baseline in FEV1 and FVC within the first 1 hours after dosing (mL)(Baseline, 1 hours post-dose at treatment day)
- The Time to Onset of Bronchodilator Response(Baseline, 0 to 8 hours post-dose at treatment day)
- FEV1 area under the curve from 0-3 h (FEV1 AUC 0-3 h)(3 hours)
- FVC AUC 3-6 h(3 to 6 hours)
- Change From Baseline in FEV1 and FVC within the first 30 minutes after dosing (mL)(Baseline, 30 minutes post-dose at treatment day)
- Evaluation of Safety(Baseline, 0 to 24 hours post-dose)
- Mean Maximum Change From Baseline in FEV1 and FVC over a period of 8 hours (mL)(Baseline, 0 to 8 hours post-dose at treatment day)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 3
Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination Nebuliser Solutions in Stable Chronic Obstructive Pulmonary Disease (COPD) PatientsCOPDNCT05890638Neutec Ar-Ge San ve Tic A.Ş74
Completed
Phase 2
Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT02260011Boehringer Ingelheim41
Completed
Phase 4
Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPDCOPDNCT02541006Neutec Ar-Ge San ve Tic A.Ş58
Completed
Phase 2
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.Pulmonary Disease, Chronic ObstructiveNCT00528996Boehringer Ingelheim2,080
Completed
Phase 2
A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThalerAsthmaNCT02148120Chiesi Farmaceutici S.p.A.60